The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

IV. Airway involvement

IV.d Cough (lone)

V. Pleural and/or pericardial involvement

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

X. Systemic/Distant conditions, syndromes and reactions

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

XI. Miscellaneous

XI.c Pleuritic chest pain

XV. Pathology

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVII. Infections & related conditions

XVII.f Tuberculosis, miliary

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.a BAL: An excess proportion of lymphocytes

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.b BAL: An excess proportion of neutrophils

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.c BAL: An excess proportion of eosinophils

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.l Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.m ILD with a granulomatous component

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

IV. Airway involvement

IV.d Cough (lone)

V. Pleural and/or pericardial involvement

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VII. Mediastinal involvement

VII.a Lymphadenopathy (intrathoracic)

VII. Mediastinal involvement

VII.e Granulomatous mediastinal lymphadenopathy

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.c Upper airway obstruction other than angioedema or hematoma

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.r Myasthenia gravis - Myasthenic-like syndrome

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ab Guillain-Barré (or GB-like) syndrome (w/wo ARF)

X. Systemic/Distant conditions, syndromes and reactions

X.g Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.l Systemic granulomatosis other than Xk

X. Systemic/Distant conditions, syndromes and reactions

X.m Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.u Multiple organ dysfunction/failure (MODS/MOF)

XV. Pathology

XV.e Path: ILD with a granulomatous component (see also Im)

XV. Pathology

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XV. Pathology

XV.ba Path: Granulomatous lymphadenopathy

XV. Pathology

XV.cg Path: Granulomatous hepatitis

XVI. Imaging

XVI.u Imaging: A miliary pattern (diffuse random micronodules)

XVI. Imaging

XVI.ai Imaging: A 'tree-in-bud' pattern

XVII. Infections & related conditions

XVII.f Tuberculosis, miliary

XVII. Infections & related conditions

XVII.i Mycobacterium bovis/BCG infection

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.a BAL: An excess proportion of lymphocytes

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.m ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.q Pulmonary nodulosis

I. Interstitial/parenchymal lung disease

I.w Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.y Progression, acceleration or exacerbation of preexisting ILD/fibrosis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

V. Pleural and/or pericardial involvement

V.d Pleural/pericardial effusion, ANA positive (DI lupus)

V. Pleural and/or pericardial involvement

V.f Pneumothorax

V. Pleural and/or pericardial involvement

V.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

VI. Pulmonary vasculopathy

VI.a Pulmonary embolism - Venous thrombosis/thromboembolism

VI. Pulmonary vasculopathy

VI.d Pulmonary vasculitis or capillaritis

VII. Mediastinal involvement

VII.a Lymphadenopathy (intrathoracic)

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.a Angioedema (may cause UAO, asphyxia and death)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.q Obstructive sleep apnea

X. Systemic/Distant conditions, syndromes and reactions

X.b Antiphospholipid antibodies w/wo the APL syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.j Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.k Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.m Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.s Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.ac Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)

X. Systemic/Distant conditions, syndromes and reactions

X.ar Relapse/flare/onset of Crohn's disease

XI. Miscellaneous

XI.ad Granulomas on tattoo edges

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XV. Pathology

XV.a Path: NSIP-cellular pattern (see also Ia, Ib)

XV. Pathology

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XV. Pathology

XV.e Path: ILD with a granulomatous component (see also Im)

XV. Pathology

XV.ba Path: Granulomatous lymphadenopathy

XVII. Infections & related conditions

XVII.a Respiratory tract infection incl. pneumonia

XVII. Infections & related conditions

XVII.b Opportunistic pulmonary/systemic infections

XVII. Infections & related conditions

XVII.f Tuberculosis, miliary

XVII. Infections & related conditions

XVII.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XVII. Infections & related conditions

XVII.h Nontuberculous pulmonary mycobacterial infection/superinfection

XVII. Infections & related conditions

XVII.ab Protozoan infection (incl. leishmaniasis)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.e Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.w Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.y Progression, acceleration or exacerbation of preexisting ILD/fibrosis

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

V. Pleural and/or pericardial involvement

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

V. Pleural and/or pericardial involvement

V.d Pleural/pericardial effusion, ANA positive (DI lupus)

VI. Pulmonary vasculopathy

VI.a Pulmonary embolism - Venous thrombosis/thromboembolism

VI. Pulmonary vasculopathy

VI.d Pulmonary vasculitis or capillaritis

X. Systemic/Distant conditions, syndromes and reactions

X.a DRES syndrome - DRESS-like reaction

X. Systemic/Distant conditions, syndromes and reactions

X.b Antiphospholipid antibodies w/wo the APL syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.g Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.h Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

X. Systemic/Distant conditions, syndromes and reactions

X.j Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.k Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.s Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.ah Granulomatosis with polyangiitis (typically ANCA pos.) - GPA flare

X. Systemic/Distant conditions, syndromes and reactions

X.ar Relapse/flare/onset of Crohn's disease

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XII. Cardiovascular involvement / toxicity

XII.q Pericarditis (see also under XIIc)

XII. Cardiovascular involvement / toxicity

XII.br Right ventricular thrombus/thrombosis

XV. Pathology

XV.a Path: NSIP-cellular pattern (see also Ia, Ib)

XV. Pathology

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XV. Pathology

XV.cs Path: Pleural granulomas

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVII. Infections & related conditions

XVII.b Opportunistic pulmonary/systemic infections

XVII. Infections & related conditions

XVII.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XVII. Infections & related conditions

XVII.d Pneumocystis jiroveci pulmonary colonization

XVII. Infections & related conditions

XVII.e Pneumocystis jiroveci pneumonia

XVII. Infections & related conditions

XVII.f Tuberculosis, miliary

XVII. Infections & related conditions

XVII.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XVII. Infections & related conditions

XVII.h Nontuberculous pulmonary mycobacterial infection/superinfection

XVII. Infections & related conditions

XVII.n Legionella pneumophila pneumonia

XVII. Infections & related conditions

XVII.o Nocardia pulmonary/systemic infection

XVII. Infections & related conditions

XVII.q Viral pneumonia

XVII. Infections & related conditions

XVII.r Fungal infection (pulmonary/extrapulmonary)

XVII. Infections & related conditions

XVII.y Cryptococcus pulmonary and/or systemic infection

XVII. Infections & related conditions

XVII.z Histoplamosis (reactivation)

XVII. Infections & related conditions

XVII.ac Actinomycosis

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.m ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.q Pulmonary nodulosis

I. Interstitial/parenchymal lung disease

I.w Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.y Progression, acceleration or exacerbation of preexisting ILD/fibrosis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.d Alveolar hemorrhage, diffuse (ANCA-positive/-related)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

V. Pleural and/or pericardial involvement

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

V. Pleural and/or pericardial involvement

V.d Pleural/pericardial effusion, ANA positive (DI lupus)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.q Obstructive sleep apnea

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.t CNS involvement/dysfunction/damage

X. Systemic/Distant conditions, syndromes and reactions

X.b Antiphospholipid antibodies w/wo the APL syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.g Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.j Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.k Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.m Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.p Serum sickness-like reaction

X. Systemic/Distant conditions, syndromes and reactions

X.s Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.x ANCA positivity. Subclinical or with clinical manifestations

X. Systemic/Distant conditions, syndromes and reactions

X.ae Antisynthetase antibodies (ASA) - ASA syndrome

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XV. Pathology

XV.ba Path: Granulomatous lymphadenopathy

XV. Pathology

XV.cs Path: Pleural granulomas

XVII. Infections & related conditions

XVII.a Respiratory tract infection incl. pneumonia

XVII. Infections & related conditions

XVII.b Opportunistic pulmonary/systemic infections

XVII. Infections & related conditions

XVII.d Pneumocystis jiroveci pulmonary colonization

XVII. Infections & related conditions

XVII.e Pneumocystis jiroveci pneumonia

XVII. Infections & related conditions

XVII.f Tuberculosis, miliary

XVII. Infections & related conditions

XVII.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XVII. Infections & related conditions

XVII.h Nontuberculous pulmonary mycobacterial infection/superinfection

XVII. Infections & related conditions

XVII.m Fungal airway infection

XVII. Infections & related conditions

XVII.n Legionella pneumophila pneumonia

XVII. Infections & related conditions

XVII.q Viral pneumonia

XVII. Infections & related conditions

XVII.r Fungal infection (pulmonary/extrapulmonary)

XVII. Infections & related conditions

XVII.v Strongyloides stercoralis hyperinfection (w/wo DAH)

XVII. Infections & related conditions

XVII.y Cryptococcus pulmonary and/or systemic infection

XVII. Infections & related conditions

XVII.z Histoplamosis (reactivation)

XVII. Infections & related conditions

XVII.ab Protozoan infection (incl. leishmaniasis)

XVII. Infections & related conditions

XVII.ak Mycobacterium leprae infection (Leprosy)